Summary. Seven of eight hypertensive Type 2 (non-insulindependent) diabetic patients with microalbuminuria completed a randomised crossover trial to compare the renal effects of angiotensin converting enzyme inhibitor (enalapril) and calcium antagonist (nicardipine). Four-week fixed oral maintenance dosages of enalapril (10-20 rag/day) and nicardipine (60-120 rag/day) significantly (p<0.05) lowered the systolic and diastolic blood pressures without altering renal blood flow, glomerular filtration rate and filtration fraction. Both drugs significantly reduced (p< 0.05) urinary albumin excretion rate and fractional clearance of albumin to similar extents. Total renal vascular resistance decreased significantly by nicardipine (p<0.05) and non-significantly by enalapril. Plasma osmotic pressure, plasma aldosterone concentration, total serum protein concentration, serum electrolytes and HbAlc remained unchanged by these drugs, whereas plasma renin activity was significantly higher (/7<0.05) in the enalapril than in the control and nicardipine phases. These results suggest that both drugs have similar renal function preserving effects with a concomitant hypotensive action in hypertensive Type 2 diabetic patients with microalbuminuria, and that the angiotensin converting enzyme inhibitor may not have advantageous renal effects when compared to the calcium antagonist and vice versa. Both drugs might be useful for treatment of high blood pressure in hypertensive diabetic patients, if long-term studies of these drugs can be shown to benefit the patients over other conventional antihypertensive therapies.
Hypertension contributes to the leading causes of morbidity and mortality in diabetic patients, such as coronary heart disease and endstage renal disease [1] . Hypertension is often associated with diabetic nephropathy [2] , and effective antihypertensive treatment has proven to be effective in slowing the progression rate of nephropathy [3] [4] [5] . Recent studies in patients with diabetic nephropathy suggest that the use of angiotensin converting enzyme (ACE) inhibitors may possess specific advantages in decreasing proteinuria and slowing progression of nephropathy [6] [7] [8] [9] . Nevertheless, whether such renal effects can be seen only with ACE inhibitors or whether ACE inhibitors have more beneficial renal effects as compared to other conventional antihypertensive drugs is uncertain. Most of the clinical trials on ACE inhibitors in these patients lack a controlled comparison with other active antihypertensive drug(s).
In Type 2 (non-insulin-dependent) diabetic patients, the major cause of the increased morbidity and mottality is cardiovascular diseases [10] . Beta-blockers and calcium antagonists are widely used groups of medication for treatment of hypertension and/or ischaemic heart disease(s) in these patients. The use of such drugs appears to be a rational choice since these drugs possess both hypotensive and cardioprotective properties [11] . A few clinical studies have suggested that calcium antagonists lower blood pressure without deterioration of renal function in hypertensive patients [12] [13] [14] [15] or even improve the renal function in hypertensive patients with kidney impairment [13] . These observations may suggest that calcium antagonists might also have a promising potential for the treatment of hypertension in diabetic patients with nephropathy.
The present study was designed to investigate and compare the renal effects of oral maintenance doses of ACE inhibitor, enalapril, and calcium antagonist, nicardipine, in hypertensive Type 2 diabetic patients with microalbuminuria. 
Subjects and methods

Patients
Eight hypertensive Japanese patients with Type 2 diabetes mellitus were studied. The patients were selected on the bases of age (45-65 years), normal serum ereatinine level (45-130 lxmol/1), increased urinary albumin excretion (41-105 mg/day) and negative urine culture. The study was performed after an informed consent had been obtained from each patient. Secondary hypertension was excluded by routine screening test, as previously described [16] . Patients with heart failure, symptomatic coronary heart disease, respiratory disease, tachyarrythmia, liver dysfunction, or clinical or laboratory evidence of other renal disease were also excluded from the study. No drugs (except oral hypoglycaemic agent and insulin) were given for at least 2 weeks before the study. The diagnosis of hypertension was confirmed when the mean of two or more diastolic and systolic blood pressures on at least two separate occasions within I month were > 95 mm Hg or > 160 mm Hg respectively. Blood pressure was mesured with a standard sphygmomanometer (cuff 25 x 12 cm) in the fight arm with the patient seated and his/her arm resting on a desk for at least 5 rain. Diastolic blood pressure was recorded at the disappearance of the Korotkoff sounds (phase V). Diagnosis of microalbuminuria was made when the mean urinary albumin excretion in three 24 h urine collections performed at home during normal activity was 30 300 mg/day [17] .
Protocol
The study was carried out in a randomised two-way crossover and double-blind fashion, using a double dummy technique. Each patient received placebos on a single-blind basis for 2 weeks as a control runin phase. Patients were then randomly allocated to receive either active enalapril with nicardipine-placebo or active nicardipine with enalapril-placebo. Four patients first received enalapril as the first active drug, followed immediately by nicardipine as the second active drug. The remaining four patients were treated in the reverse order. Placebo preparations of enalapril and nicardipine were identical to the respective active tablets. The placebo wash-out period was not located between the two active-drug phases to avoid a possible withdrawal or rebound phenomenon [18] . Such a study design, without a double blind placebo period between the active treatment phases, appears to be ethically reasonably [19] . The initial dosages of enalapril and nicardipine were 5 mg twice daily and 20 mg trice daily, and these were increased to 10 mg twice daily and 40 mg trice daily, respectively during the 2 week titration period in patients whose diastolic or systolic blood pressure remained above 95 mm Hg or 160 mm Hg, respectively. These titrating dosage schemes have been reported to be effective for lowering blood pressure in essential hypertension [20, 21] .
Renal function tests were examined at the end of 2 week control run-in phase and of 4 week fixed maintenance phases of enalapril and nicardipine. Blood samples for measurements of plasma renin activity (PRA), aldosterone concentration (PAC), osmotic pressure, serum total protein concentration and HbAlc and urine samples for measurement of albumin excretion rate (AER) were collected during the 120 min renal function study. The final dose of placebo, enalapril or nicardipine was administered at 08.00 hours on the last day of each trial period. Renal function measurements were started at 12.00 hours and made in the recumbent position after 60 min of supine rest.
Side effects reported by the patients at each of the clinical visits were recorded by one of the investigators but were not evaluated rigorously according to special ascertainment methodology.
Measurements
Renal blood flow (RBF) and glomerular filtration rate (GFR) were measured by means of renal clearance methods using sodium paraaminohippurate and sodium thiosulfate according to the techniques as described in our previous reports [16, 22] . Total renal vascular resistance (TRR) was calculated by the following formula [23] : (mean blood pressure -renal venous pressure) x 8 x 104/RBF (dyne-s-1. cm-s), where the mean blood pressure was calculated as diastolic blood pressure plus one-third pulse pressure and the renal venous pressure was substituted by 10 mm Hg. Filtration fraction (FF) was expressed as the GFR/renal plasma flow (RPF) ratio. Fractional clearance of albumin was calculated as; the clearance of albumin/GFR. Serum total protein concentration was measured in an Auto-Analyzer (SMAC I, Technicon, Tarrytown, NY, USA). PRA [24] , PAC [25] and urinary albumin (normal range 0.3-13.4~tg/min [26] were measured by the respective radioimmunoassay. Hblc was measured by high-performance liquid chromatography [27] on a cation-exchange minicolumn (Auto Alc HA-8110, Kyoto Daiichi Kagaku, Kyoto, Japan) (normal range 3.3-5.2% of total). Plasma osmotic pressure was determined by the freezing point method [28] in an Osmotic Pressure AUTO & STAT OM-6010 (Kyoto Daiichi Kagaku, Kyoto, Japan).
Statistical analysis
All data are presented as means (SEM), except for AER, fractional clearance of albumin, TRR and PRA, which are shown as median and range values because of their skew distributions. Differences in measurements among the three trial phases are assessed by one-way layout analysis of variance (ANOVA), and where the overall difference between phases proved to be significant, comparison was made by the least significant difference (LSD) method. The correlation between the drug-induced change (%) in AER and FF or TRR was analysed by Spearman's method with calculation of the rank coefficient value (rs). All statistical analysis were performed with a PC-9801 computer (NEC, Tokyo, Japan). A p value less than 5% was considered significant. Value are given as means (SEM) or (range). a p < 0.05 from control phase; b p < 0.01 from control phase; c < 0.05 from nicardipine phase. Urinary albumin excretion rate and fractional clearance of albumin were assessed during the renal function tests performed in recumbent position
Results
Seven of 8 patients completed the whole course of the trials. One female patient was withdrawn from the study because she developed an intolerable cough three weeks after the initiation of enalapril. The cough diminished 2 days after the cessation of the therapy. One male patient complained of palpitation on the first day of nicardipine, in whom treatment was continued with unchanged dosage and the symptom lessened. Therefore, data reported here come from the seven patients who completed the entire trial. The clinical characteristics of the seven patients are summarised in Table 1 . Data for blood pressure, body mass index, serum creatinine and AER were obtained before each patient was enrolled in the study. Haemodynamic and renal function parameters, AER, PRA and PAC measured on the final days of the three trial phases are summarised in Table 2 . The oral administrations of enalapril and nicardipine significantly reduced (p<0.01) both systolic and diastolic blood pressures, respectively as compared to the control values. Systolic blood pressure in the enalapril phase was slightly, but not significantly, higher than that in the nicardipine phase. Heart rate measured at the same times was affected by neither drugs. Two patients required 10 mg/day and five required 20 rag/day enalapril, while four required 60 mg/day and three did 120mg/day nicardipine to achieve the satisfactory blood pressure control.
Both RBF and GFR increased slightly by treatments with enalapril and nicardipine. However, the changes in RBF and GFR produced by these drugs in individual patient were inconsistent or variable and the mean RBF and GFR did not differ in the three trials. In contrast, five patients on enalapril and all patients on nicardipine showed a decrease in TRR. The mean TRR was significantly lower (p< 0.05, -25.4 [7.7] 
Discussion
Oral administration of enalapril and nicardipine reduced both systolic and diastolic blood pressures in the seven hypertensive Type 2 diabetic patients with microalbuminuria. The hypotensive effect of these drugs are similar to those observed previously with enalapril in hypertensive Type 1 (insulin-dependent) diabetic patients [9] and nicardipine in patients with essential hypertension [14] . The slight difference in magnitude of blood pressure reduction might be due to differences in the vasodilating potency of the two agents at the doses employed. Patients' PRA profile [291, vascular distensibility [30] could also influence the hypotensive effect of these drugs.
The renal haemodynamic response to enalapril and nicardipine were similar in our patients. Such renal effects of the drugs (i. e. unchanged or slight increase in RBF and decrease in TRR) can be explained by renal vasodilatation induced by these drugs and autoregulation of renal circulation. In fact, oral administration of enalapril [31, 32] and nicardipine [14] have been reported to maintain RBF and GFR with a reduction in renal vascular resistance in patients with essential hypertension. Since increased renal vascular resistance has been reported as an underlying haemodynamic abnormality in microalbuminuric diabetic patients with minimally elevated blood pressure levels [33] , the finding that these drugs caused a reduction in blood pressure and TRR in hypertensive diabetic patients might be promising. Nevertheless, whether these drugs restitute GFR without inducing further glomerular damage is a remaining question. And whether the drug-induced slight increment in RBF would be harmful in terms of the current concern about glomerular hyperfiltration in diabetic patients possibly being involved with progression of diabetic nephropathy [18] remains to be determined.
The mean AER and fractional clearance of albumin decreased similarly by both enalapril and nicardipine therapies. The observation is consistent with a previous report that blood pressure control is an important factor in reducing urinary albumin excretion in hypertensive diabetic patients with microalbuminurla [33] . The present study, however, cannot totally exclude a possibility that an ACE inhibitor might cause more profound reduction in AER when 24 h urine samples are used, which include influence of posture, exercise and/or daily life activity. These physical activity could stimulate the production of angiotensin II, and ACE inhibitor could suppress its production. It is not known yet, however, whether such an effect on the intra-and extrarenal renin-angiotensin systems in a long-term use would cause any benefit or harm to the diabetic complications. Dietary protein is another determinant of albuminuria [34, 351. Nevertheless, it seems unlikely that the reduction in albuminuria can be entirely explained by a change in dietary protein intake during the trials. The study was a within-subject comparison and, if the possible variability in protein intake would have existed during the control phase in each patient, the similar variability would have occurred in the same individuals during the active drug phases. The lower AER in the control phase (Table 2 ) as compared to the pretrial AER (Table 1) can be explained by the differences in patients' position and magnitude of physical activity during the urine collection [36, 37] .
Hypertension is a risk factor of cardiovascular events in Type 2 diabetic patients with microalbuminuria [38] . It seems established that high blood pressure in these patients should be adequately controlled, regardless its pathophysiological mechanism(s) behind the development of hypertension. If the ultimate basis of antihypertensive therapy is not only to lower blood pressure, but also to include preservation of regional circulation, the use of the drugs, which interfere with one or more vasoconstrictor mechanisms in order to reverse the underlying renal haemodynamic abnormality, might be a logical approach. However, the present findings should be interpreted with some caution. First, patients must be followed for severel years until reliable and meaningful data may be obtained [391 to evaluate whether a treatment is truly beneficial for the patients or not. Second, Parving et al. showed that effective antihypertensive treatment with metoprolol, hydralazin and furosemide could slow the progression of nephropathy [5, 40] . The rate of decline in GFR with those drugs (0.37ml.min-a.month -1 [401, 0.22ml.min -1 9 month -t [5] , 0.49ml-min-l-month -1 [3] ) appears to be comparable to the rate with enalapril (0.40 ml. min-l-month -a [411, 0.20ml-min-l.month -1 [71). These observations might suggest that the beneficial effect of antihypertensive treatment on renal function is related to the good control of blood pressure rather than to the class of drug used.
In conclusion, we did not find any difference in renal effects of enalapril and nicardipine in this shortterm study with hypertensive Type', 2 diabetic patients with microalbuminuria. It remains to be seen whether the initiation of antihypertensive treatment with ACE inhibitor or calcium antagonist at an early stage of nephropathy would have a more effective long-term beneficial impact over other antihypertensive agents on the progression of nephropathy and cardiovascular morbidity and mortality in diabetic patients. Until further studies ascertain the long-term renal functional effectiveness and safety of these drugs in diabetic patients over a wide range of nephropathy and hypertension, our results should be viewed as a preliminary basis for future studies.
